SCHEMBL24601106

SCHEMBL24601106

CC(C)(C)OC(=O)NS(=O)(=O)NCCC1CCN(c2ccnc3[nH]c(=O)ccc23)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP1 P22413 7/20 0.41
CA12 O43570 2/20 0.39
CA14 Q9ULX7 2/20 0.39
CA1 P00915 1/20 0.39
CA7 P43166 1/20 0.39
SIRT2 Q8IXJ6 2/20 0.37
SIRT1 Q96EB6 2/20 0.37
SIRT3 Q9NTG7 2/20 0.37
CKS1B P61024 1/20 0.35
SKP1 P63208 1/20 0.35
SKP2 Q13309 1/20 0.35
CCNT1 O60563 2/20 0.34
CDK9 P50750 2/20 0.34
EIF2AK4 Q9P2K8 1/20 0.34
CA2 P00918 1/20 0.34
PBK Q96KB5 1/20 0.34
ACACB O00763 1/20 0.34
ACACA Q13085 1/20 0.34
DRD2 P14416 1/20 0.33
AKT2 P31751 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24600618 0.92 CA12 (0.40) ENPP1CA12CA14CA1CA7
SCHEMBL29691616 0.87 SIRT2 (0.47) ENPP1SIRT2SIRT1SIRT3CKS1B
SCHEMBL24601078 0.87 SIRT2 (0.47) ENPP1SIRT2SIRT1SIRT3CKS1B
SCHEMBL24601082 0.86 CKS1B (0.40) ENPP1CKS1BSKP1SKP2CCNT1
SCHEMBL29691669 0.86 CKS1B (0.40) ENPP1CKS1BSKP1SKP2CCNT1
SCHEMBL29248790 0.83 ENPP1 (0.45) ENPP1SIRT2SIRT1SIRT3PBK
SCHEMBL29691484 0.83 CKS1B (0.50) ENPP1CKS1BSKP1SKP2PBK
SCHEMBL24600959 0.83 CKS1B (0.50) ENPP1CKS1BSKP1SKP2PBK
SCHEMBL26679840 0.82 ENPP1 (0.42) ENPP1SIRT2SIRT1SIRT3AKT2
SCHEMBL24600681 0.81 ENPP1 (0.48) ENPP1AKT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240140944-A1 NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF TXINNO BIOSCIENCE INC. (KR) 2024-05-02 US disclosed
EP-4276100-A1 NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF Txinno Bioscience Inc. (KR) 2023-11-15 EP disclosed
WO-2022146022-A1 NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF 주식회사 티씨노바이오사이언스 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240140944-A1 NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF ENPP1, ENPP3, ENTPD5 ENPP1 1/4885CA12 4565/4885CA14 4616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.